Vericel Corp. (NASDAQ:VCEL) shares were up 3.8% on Thursday . The stock traded as high as $2.38 and last traded at $2.21, with a volume of 504,281 shares. The stock had previously closed at $2.13.

Several research analysts recently weighed in on VCEL shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 target price on shares of Vericel Corp. in a report on Tuesday, April 5th. Bank of America Corp. downgraded shares of Vericel Corp. from a “buy” rating to a “neutral” rating in a report on Tuesday, April 5th.

The stock’s market capitalization is $48.90 million. The firm has a 50-day moving average of $2.33 and a 200 day moving average of $2.78.

Vericel Corp. (NASDAQ:VCEL) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.17. The company had revenue of $14.10 million for the quarter, compared to analyst estimates of $11.60 million. On average, analysts expect that Vericel Corp. will post ($0.79) earnings per share for the current fiscal year.

Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.